Pimecrolimus 1% vs Placebo for Facial Vitiligo: Randomized Controlled Trial Overview
Key Takeaways Pimecrolimus 1% cream showed superiority to vehicle on facial endpoints (F-VASI) over ~12–24 weeks in split-face and parallel-arm […]
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Face/neck consistently show the best repigmentation with tacrolimus 0.1%; early perifollicular islands predict response. Acral (hands/feet) and longstanding
Vitiligo Diagnosis: Wood’s Lamp, Dermoscopy, and Differential Workup
Key Takeaways Wood’s lamp: vitiligo shows bright chalk-white fluorescence with sharp borders; early lesions highlight margins before clinical contrast is
Excimer 308 nm in Vitiligo: Focal Therapy for Face/Neck and Acral Margins
Key Takeaways Targeted 308 nm is effective for limited facial/neck lesions and expanding edges of patches. Acral sites (hands/feet) respond slower;
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Safety (n≈150–200)
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo with best responses on face/neck; acral lesions remain hardest. Typical schedules: 2–3×/week, incremental
Oxidative Stress in Vitiligo: Catalase Defects, H2O2 Accumulation, and Antioxidant Pathways
Key Takeaways Lesional epidermis often shows reduced catalase activity and increased H2O2, contributing to melanocyte stress and antigen exposure. Systemic
Autoimmunity in Vitiligo: IFN-γ–CXCL9/10 Axis and Tissue-Resident Memory T Cells (TRM)
Key Takeaways IFN-γ induces keratinocyte/immune-cell secretion of CXCL9/10, recruiting CXCR3+ cytotoxic T cells that kill melanocytes. CD8+ TRM persist in
Tofacitinib in Vitiligo: Case Series and Open-Label Studies ± NB-UVB
Key Takeaways Tofacitinib (JAK1/3 inhibitor) has shown facial repigmentation in multiple case series; responses improve with concurrent light (NB-UVB or
Ruxolitinib 1.5% Cream in Nonsegmental Vitiligo: TRuE-V2 Phase 3 Results
Key Takeaways TRuE-V2 confirmed facial repigmentation superiority of ruxolitinib 1.5% cream versus vehicle at ~24 weeks, mirroring TRuE-V1. Continued treatment